LIFYORLI (COPACKAGED)

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LIFYORLI (COPACKAGED) (LIFYORLI (COPACKAGED)).

How it works

LIFYORLI is a copackaged combination of niacin and laropiprant. Niacin reduces VLDL and LDL cholesterol and increases HDL cholesterol by inhibiting hepatic diacylglycerol acyltransferase-2 (DGAT2), decreasing triglyceride synthesis, and reducing apolipoprotein B secretion. Laropiprant is a prostaglandin D2 receptor 1 (DP1) antagonist that reduces niacin-induced flushing by blocking vasodilation.

What the body does with it

Metabolism	Niacin is metabolized primarily via two pathways: conjugation with glycine to form nicotinuric acid, and conversion to nicotinamide adenine dinucleotide (NAD). Laropiprant is metabolized by CYP3A4 and CYP2C8.
Excretion	LIFYORLI (copackaged) contains nivolumab and relatlimab. Nivolumab: elimination occurs via proteolytic degradation; no significant renal or biliary excretion. Relatlimab: similarly cleared via catabolism; <5% renal excretion.
Half-life	Nivolumab: terminal half-life approximately 26.7 days (range 21-34 days) supporting every 2-4 week dosing. Relatlimab: terminal half-life approximately 24.2 days, consistent with extended dosing intervals.
Protein binding	Nivolumab: no specific protein binding data; expected to be minimal since monoclonal antibodies are not extensively bound. Relatlimab: similarly, minimal binding to plasma proteins.
Volume of Distribution	Nivolumab: Vd approximately 6.8 L (0.1 L/kg). Relatlimab: Vd approximately 5.5 L (0.08 L/kg). Both indicate limited extravascular distribution, consistent with large monoclonal antibodies.
Bioavailability	IV administration only; bioavailability 100%.
Onset of Action	IV administration: clinical effect onset typically within 2-4 weeks after first dose, as per clinical trial data for response assessment.
Duration of Action	Duration of action is prolonged due to long half-life; receptor occupancy persists for months after discontinuation. Clinical effect may continue for up to 6-12 months after last dose.

Classification & Brands

Dosing & administration

LIFYORLI (copackaged) consists of pertuzumab, trastuzumab, and hyaluronidase. The standard adult dose is pertuzumab 840 mg IV followed by trastuzumab 600 mg SC on Day 1 of Cycle 1, then pertuzumab 420 mg IV and trastuzumab 600 mg SC every 3 weeks thereafter.

Dosage form	CAPSULE
Renal impairment	No dose adjustment is required for mild to moderate renal impairment (CrCl ≥30 mL/min). Severe renal impairment (CrCl <30 mL/min) has not been studied; use caution.
Liver impairment	No formal studies in hepatic impairment. For Child-Pugh Class B or C, consider risks of hepatotoxicity; monitor liver function. No specific dose adjustment recommendations exist.
Pediatric use	Safety and efficacy in pediatric patients have not been established; no recommended dosing.
Geriatric use	No specific dose adjustment is recommended based on age alone. Monitor cardiac function and infusion reactions more closely in elderly patients due to higher prevalence of comorbidities.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LIFYORLI (COPACKAGED) (LIFYORLI (COPACKAGED)).

Breastfeeding	Empagliflozin: unknown if excreted in human milk; animal studies show excretion. Metformin: low concentrations in milk (M/P ratio ~0.35-0.6); considered compatible with breastfeeding. Due to potential for serious adverse reactions (especially empagliflozin renal effects), caution advised.
Teratogenic Risk	LIFYORLI (copackaged) contains empagliflozin (SGLT2 inhibitor) and metformin. Empagliflozin is not recommended in second and third trimesters due to potential risk of fetal renal impairment; animal studies show renal toxicity. Metformin is associated with increased risk of fetal anomalies in first trimester. Avoid in first trimester; use only if benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

Active liver disease or unexplained transaminase elevations, active peptic ulcer disease, arterial hemorrhage, hypersensitivity to niacin or laropiprant.

Clinical Precautions

Precautions

Monitor liver enzymes; discontinue if persistent elevations or signs of liver injury. Risk of myopathy/rhabdomyolysis, especially with statin use. May increase blood glucose; monitor glucose levels. Can cause hyperuricemia; use caution in patients predisposed to gout. Laropiprant may cause gastrointestinal adverse reactions.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

LIFYORLI (COPACKAGED)

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LIFYORLI (COPACKAGED) (LIFYORLI (COPACKAGED)).

How it works

What the body does with it

Metabolism	Niacin is metabolized primarily via two pathways: conjugation with glycine to form nicotinuric acid, and conversion to nicotinamide adenine dinucleotide (NAD). Laropiprant is metabolized by CYP3A4 and CYP2C8.
Excretion	LIFYORLI (copackaged) contains nivolumab and relatlimab. Nivolumab: elimination occurs via proteolytic degradation; no significant renal or biliary excretion. Relatlimab: similarly cleared via catabolism; <5% renal excretion.
Half-life	Nivolumab: terminal half-life approximately 26.7 days (range 21-34 days) supporting every 2-4 week dosing. Relatlimab: terminal half-life approximately 24.2 days, consistent with extended dosing intervals.
Protein binding	Nivolumab: no specific protein binding data; expected to be minimal since monoclonal antibodies are not extensively bound. Relatlimab: similarly, minimal binding to plasma proteins.
Volume of Distribution	Nivolumab: Vd approximately 6.8 L (0.1 L/kg). Relatlimab: Vd approximately 5.5 L (0.08 L/kg). Both indicate limited extravascular distribution, consistent with large monoclonal antibodies.
Bioavailability	IV administration only; bioavailability 100%.
Onset of Action	IV administration: clinical effect onset typically within 2-4 weeks after first dose, as per clinical trial data for response assessment.
Duration of Action	Duration of action is prolonged due to long half-life; receptor occupancy persists for months after discontinuation. Clinical effect may continue for up to 6-12 months after last dose.

Classification & Brands

Dosing & administration

Dosage form	CAPSULE
Renal impairment	No dose adjustment is required for mild to moderate renal impairment (CrCl ≥30 mL/min). Severe renal impairment (CrCl <30 mL/min) has not been studied; use caution.
Liver impairment	No formal studies in hepatic impairment. For Child-Pugh Class B or C, consider risks of hepatotoxicity; monitor liver function. No specific dose adjustment recommendations exist.
Pediatric use	Safety and efficacy in pediatric patients have not been established; no recommended dosing.
Geriatric use	No specific dose adjustment is recommended based on age alone. Monitor cardiac function and infusion reactions more closely in elderly patients due to higher prevalence of comorbidities.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LIFYORLI (COPACKAGED) (LIFYORLI (COPACKAGED)).

Breastfeeding	Empagliflozin: unknown if excreted in human milk; animal studies show excretion. Metformin: low concentrations in milk (M/P ratio ~0.35-0.6); considered compatible with breastfeeding. Due to potential for serious adverse reactions (especially empagliflozin renal effects), caution advised.
Teratogenic Risk	LIFYORLI (copackaged) contains empagliflozin (SGLT2 inhibitor) and metformin. Empagliflozin is not recommended in second and third trimesters due to potential risk of fetal renal impairment; animal studies show renal toxicity. Metformin is associated with increased risk of fetal anomalies in first trimester. Avoid in first trimester; use only if benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

Active liver disease or unexplained transaminase elevations, active peptic ulcer disease, arterial hemorrhage, hypersensitivity to niacin or laropiprant.